CoChat

Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel

Open access
Fitzpatrick, John M., Bellmunt, Joaquim, Fizazi, Karim, Heidenreich, Axel, Sternberg, Cora N., Tombal, Bertrand, Alcaraz, Antonio, Bahl, Amit, Bracarda, Sergio, Di Lorenzo, Giuseppe, Efstathiou, Eleni, Finn, Stephen P., Fosså, Sophie, Gillessen, Silke, Kellokumpu-Lehtinen, Pirkko-Liisa, Lecouvet, Frédéric E., Oudard, Stephane, de Reijke, Theo M., Robson, Craig N., De Santis, Maria, Seruga, Bostjan, de Wit, Ronald · 2014 · European Journal of Cancer
Cited by 145

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2014.03.010

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 145

Metadata

Authors
Fitzpatrick, J. M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C. N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S. P., Fosså, S., Gillessen, S., Kellokumpu-Lehtinen, P.-L., Lecouvet, F. E., Oudard, S., de Reijke, T. M., Robson, C. N., De Santis, M., Seruga, B., & de Wit, R.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2014-06
Volume
50
Issue
9
Pages
1617-1627
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2150418305
Cited by
145
References
7
FWCI
17.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.